Gene Therapy Drug Development for First-In-Human Study of Pediatric Diseases: Facilitating Change to Current Paradigms
Main Article Content
Abstract
Drug development in pediatrics is mandated under US and European Union legislation, and delays in pediatric studies can impact the appropriate labeling and use of therapeutics for children. Developing medical products for pediatrics is challenging, as there are several critical issues and factors to consider when initiating a pediatric drug development program. The International Conference Harmonisation guideline E11(R1) and criteria under 21 CFR part 50 subpart D define pediatric regulatory standards for drug developers and ensure the safety of pediatric participants in clinical studies.
Adequate adult data are typically required before finalizing pediatric study designs and initiating pediatric studies by virtue of the Pediatric Research Equity Act. It is evolving that the Food and Drug Administration (FDA) is including adolescents in Phase 3 trials. In pediatrics, the lack of coordinated use of extrapolation for safety and efficacy amongst global regulatory agencies impacts the timelines and development of clinical trial designs. First-in-human pediatric trials may be justified if the aspects of 21 CFR 50, subpart D specifically 21 CFR 50.52 are addressed. For example, first-in-human pediatric gene therapy trials have been allowed in spinal muscular atrophy (SMA) using a benefit-risk assessment to justify the conduct of first-in-human trials in children. The statutory requirement to study children in clinical trials is influenced by the nature of the disease that is currently under study and needs to be personalized. These issues are addressed in this perspective on gene therapy treatment in children.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Mulberg AE, Conklin LS, Croft NM, I-ACT for Children Pediatric Extrapolation Working Group. Pediatric Extrapolation of Adult Efficacy to Children Is Critical for Efficient and Successful Drug Development. Gastroenterology. 2022;163(1):77-83. doi:10.1053/j.gastro.2022.03.018
3. Only Patient in N-of-1 CRISPR Trial for Duchenne Muscular Dystrophy Dies. BioSpace. Accessed July 14, 2023. https://www.biospace.com/article/patient-in-n-of-1-crispr-trial-for-duchenne-muscular-dystrophy-dies-/
4. TaylorMay 19 NP, 2023 09:35am. DMD gene therapy death exposes risks of treating older patients. Fierce Biotech. Published May 19, 2023. Accessed July 14, 2023. https://www.fiercebiotech.com/biotech/dmd-gene-therapy-death-exposes-risks-treating-older-patients
5. 21 CFR Part 50 Protection of Human Subjects. Accessed February 6, 2023. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50
6. Research C for DE and. Benefit-Risk Assessment for New Drug and Biological Products. U.S. Food and Drug Administration. Published September 29, 2021. Accessed February 6, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products
7. CFR - Code of Federal Regulations Title 21. Accessed February 6, 2023. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.80
8. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165. doi:10.1016/0092-8674(95)90460-3
9. Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810-817. doi:10.1212/WNL.0000000000000741
10. Kolb SJ, Coffey CS, Yankey JW, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3(2):132-145. doi:10.1002/acn3.283
11. Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Annals of Neurology. 2017;82(6):883-891. doi:10.1002/ana.25101
12. Spinal Muscular Atrophy Fact Sheet | National Institute of Neurological Disorders and Stroke. Accessed January 27, 2023. https://www.ninds.nih.gov/spinal-muscular-atrophy-fact-sheet
13. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271-274. doi:10.1038/nbt.1610
14. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine. 2017;377(18):1713-1722. doi:10.1056/NEJMoa1706198
15. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284-293. doi:10.1016/S1474-4422(21)00001-6
16. Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract. 2022;4(1):2. doi:10.1186/s42466-021-00162-9
17. Downs J, Stahlhut M, Wong K, et al. Validating the Rett Syndrome Gross Motor Scale. PLoS One. 2016;11(1):e0147555. doi:10.1371/journal.pone.0147555
18. Neul JL, Kaufmann WE, Glaze DG, et al. Rett Syndrome: Revised Diagnostic Criteria and Nomenclature. Ann Neurol. 2010;68(6):944-950. doi:10.1002/ana.22124
19. Fu Y, Zhan X, Wang Y, et al. NLRC3 expression in dendritic cells attenuates CD4+ T cell response and autoimmunity. EMBO J. 2019;38(16):e101397. doi:10.15252/embj.2018101397
20. Mulberg AE, Murphy D, Dunne J, Mathis LL. Pediatric Drug Development. John Wiley & Sons; 2013.
21. Bhatnagar M, Sheehan S, Sharma I, et al. Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions. Pediatrics. 2021;147(5):e2020049602. doi:10.1542/peds.2020-049602
22. Shirkey H. Therapeutic orphans. Pediatrics. 1999;104(3 Pt 2):583-584.